FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 06/2021”.

The Monitor is a month-to-month printed overview of enterprise capital developments within the US-Biotech sector.

As of the top of June 2021, we establish the next present VC developments within the US-Biotech sector:

  • In 2021, total Biotech funding within the USA has reached USD 17,163m to date
  • High 5 offers exceed USD 330m every, largest transaction amounted to USD 735m in Treeline Biosciences, Inc.
  • Logos Capital (USA) leads the High 5 Buyers (by deal quantity), adopted by ARCH Enterprise Companions (USA) and Casdin Capital (USA)
  • Oncology dominates as the highest indication

To entry the complete report, please click on right here.

By Dr. Mathias Schott, Sebastian Sommer and Alexander Kuhn

Leave a Reply

Your email address will not be published.